Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Follow-Up Questions
What is the price performance of IFTBF stock?
The current price of IFTBF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Infant Bacterial Therapeutics AB?
Infant Bacterial Therapeutics AB belongs to Pharmaceuticals industry and the sector is Health Care
What is Infant Bacterial Therapeutics AB market cap?
Infant Bacterial Therapeutics AB's current market cap is $0
